Eflapegrastim

Names

[ Name ]:
Eflapegrastim

Biological Activity

[Description]:

Eflapegrastim is a humanized IgG4 monoclonal antibody, is also a granulocyte colony-stimulating factor (G-CSF). Eflapegrastim targets to G-CSF receptor (c-Fms). Eflapegrastim stimulates proliferation and differentiation of neutrophil progenitor cells and maintains stable numbers of mature and functional neutrophils. Eflapegrastim also shortens the duration of neutropenia[1].

[Related Catalog]:

Research Areas >> Inflammation/Immunology

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> c-Fms

[In Vitro]

Eflapegrastim 含有 IgG4 Fc 片段和短聚乙二醇连接物[1]。 Eflapegrastim (5.5-88 mM; 4 min) 与 FcRn 结合，但不与 Fcγ 受体或 C1q 结合[1]。 Eflapegrastim (0.000036-0.709 nmol/L; 54 h) 诱导骨髓细胞增殖[1]。 Eflapegrastim (10 μM; 1 h) 结合FcRn并经历FcRn介导的胞吞作用[1]。

[In Vivo]

Eflapegrastim (100 μg/kg; 皮下注射; 单次剂量) 降低化疗诱导的中性粒细胞减少大鼠中性粒细胞减少 (DN) 的持续时间，增加血清和骨髓中 G-CSF 的水平[1]。 Animal Model: C57BL/6NCrl mice (4-6 weeks old)[1] Dosage: (1) 9, 26, 53, and 88 µg/kg; (2) 62 µg/kg Administration: Subcutaneous injection; single dose Result: Reduced chemotherapy-induced neutropenia.

[References]

[1]. Barrett JA, et al. Eflapegrastim's enhancement of efficacy compared with pegfilgrastim in neutropenic rats supports potential for same-day dosing. Exp Hematol. 2020 Dec;92:51-61.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.